Abound Wealth Management’s Charles River Laboratories CRL Stock Holding History

Abound Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13K	Sell	5 -2	-29%	-$356	﹤0.01%	802
2026 Q1	$1.12K	Hold	7	–	–	﹤0.01%	974
2025 Q4	$1.3K	Buy	7 +2	+40%	+$363	﹤0.01%	889
2025 Q3	$783	Hold	5	–	–	﹤0.01%	888
2025 Q2	$759	Buy	+5	New	+$667	﹤0.01%	822
2025 Q1	–	Sell	-2	Closed	-$335	–	1259
2024 Q4	$338	Buy	2 +1	+100%	+$193	﹤0.01%	862
2024 Q3	$243	Hold	1	–	–	﹤0.01%	1058
2024 Q2	$255	Hold	1	–	–	﹤0.01%	1031
2024 Q1	$334	Buy	+1	New	+$239	﹤0.01%	1083
2023 Q4	–	Sell	-10	Closed	-$1.96K	–	1368
2023 Q3	$1.96K	Sell	10 -1	-9%	-$205	﹤0.01%	620
2023 Q2	$2.31K	Buy	11 +1	+10%	+$199	﹤0.01%	624
2023 Q1	$2.02K	Buy	+10	New	+$2.27K	﹤0.01%	587

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Abound Wealth Management's CRL Position: Q2 2026 in Review

Abound Wealth Management reduced its Charles River Laboratories (CRL) stake by 29% in Q2 2026, selling an estimated $356 and leaving 5 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #802.

Abound Wealth Management first reported a position in CRL in Q1 2023 and has held it in 12 quarters since. The position peaked at $2.31K in Q2 2023. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Abound Wealth Management held 5 shares of Charles River Laboratories worth $1.13K as of Q2 2026.
Abound Wealth Management sold 2 Charles River Laboratories shares in Q2 2026, an estimated $356.
Charles River Laboratories made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #802 holding.
Abound Wealth Management first reported a position in Charles River Laboratories in Q1 2023 and has held it in 12 quarters since.
Abound Wealth Management's Charles River Laboratories position peaked at $2.31K in Q2 2023.
563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.